• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代谢健康型肥胖:干预措施有用吗?

Metabolically Healthy Obesity: Are Interventions Useful?

作者信息

Mathis Bryan J, Tanaka Kiyoji, Hiramatsu Yuji

机构信息

International Medical Center, University of Tsukuba Hospital, Tsukuba, Ibaraki, 305-8576, Japan.

Faculty of Health and Sport Sciences, University of Tsukuba, Tsukuba, Ibaraki, 305-8575, Japan.

出版信息

Curr Obes Rep. 2023 Mar;12(1):36-60. doi: 10.1007/s13679-023-00494-4. Epub 2023 Feb 23.

DOI:10.1007/s13679-023-00494-4
PMID:36814043
Abstract

PURPOSE OF REVIEW

This review aims to detail the current global research state of metabolically healthy obesogenesis with regard to metabolic factors, disease prevalence, comparisons to unhealthy obesity, and targeted interventions to reverse or delay progression from metabolically healthy to unhealthy obesity.

RECENT FINDINGS

As a long-term condition with increased risk of cardiovascular, metabolic, and all-cause mortality risks, obesity threatens public health on a national level. The recent discovery of metabolically healthy obesity (MHO), a transitional condition during which obese persons carry comparatively lower health risks, has added to confusion about the true effect of visceral fat and subsequent long-term health risks. In this context, the evaluation of fat loss interventions, such as bariatric surgery, lifestyle changes (diet/exercise), and hormonal therapies require re-evaluation in light of evidence that progression to high-risk stages of obesity relies on metabolic status and that strategies to protect the metabolism may be useful in the prevention of metabolically unhealthy obesity. Typical calorie-based exercise and diet interventions have failed to reduce the prevalence of unhealthy obesity. Holistic lifestyle, psychological, hormonal, and pharmacological interventions for MHO, on the other hand, may at least prevent progression to metabolically unhealthy obesity.

摘要

综述目的

本综述旨在详细阐述代谢健康型肥胖发生的当前全球研究状况,内容涉及代谢因素、疾病患病率、与不健康肥胖的比较,以及旨在逆转或延缓从代谢健康型肥胖发展为不健康肥胖的针对性干预措施。

最新发现

作为一种会增加心血管疾病、代谢疾病及全因死亡风险的长期病症,肥胖在国家层面威胁着公众健康。近期发现的代谢健康型肥胖(MHO),即肥胖者在此过渡状态下健康风险相对较低,这增加了人们对内脏脂肪的真正影响及后续长期健康风险的困惑。在此背景下,鉴于有证据表明肥胖发展到高风险阶段依赖于代谢状态,且保护代谢的策略可能有助于预防代谢不健康型肥胖,对减肥干预措施(如减肥手术、生活方式改变(饮食/运动)和激素疗法)的评估需要重新审视。典型的基于卡路里的运动和饮食干预未能降低不健康肥胖的患病率。另一方面,针对代谢健康型肥胖的整体生活方式、心理、激素和药物干预至少可能预防发展为代谢不健康型肥胖。

相似文献

1
Metabolically Healthy Obesity: Are Interventions Useful?代谢健康型肥胖:干预措施有用吗?
Curr Obes Rep. 2023 Mar;12(1):36-60. doi: 10.1007/s13679-023-00494-4. Epub 2023 Feb 23.
2
Cardiovascular Risk Factors Associated With the Metabolically Healthy Obese (MHO) Phenotype Compared to the Metabolically Unhealthy Obese (MUO) Phenotype in Children.与代谢不健康肥胖(MUO)表型相比,儿童中与代谢健康肥胖(MHO)表型相关的心血管危险因素。
Front Endocrinol (Lausanne). 2020 Feb 7;11:27. doi: 10.3389/fendo.2020.00027. eCollection 2020.
3
Metabolically Healthy Obesity: Criteria, Epidemiology, Controversies, and Consequences.代谢健康型肥胖:标准、流行病学、争议与后果。
Curr Obes Rep. 2020 Jun;9(2):109-120. doi: 10.1007/s13679-020-00375-0.
4
Metabolically Healthy Obesity (MHO) vs. Metabolically Unhealthy Obesity (MUO) Phenotypes in PCOS: Association with Endocrine-Metabolic Profile, Adherence to the Mediterranean Diet, and Body Composition.多囊卵巢综合征中代谢健康型肥胖(MHO)与代谢不健康型肥胖(MUO)表型:与内分泌代谢特征、地中海饮食依从性和身体成分的关联。
Nutrients. 2021 Nov 2;13(11):3925. doi: 10.3390/nu13113925.
5
Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity.非酒精性脂肪性肝病与代谢健康或代谢不健康肥胖之间关联的流行病学和病理生理学。
Ann Hepatol. 2020 Jul-Aug;19(4):359-366. doi: 10.1016/j.aohep.2020.03.001. Epub 2020 Mar 21.
6
Natural course of metabolically healthy phenotype and risk of developing Cardiometabolic diseases: a three years follow-up study.代谢健康表型的自然病程及发生心血管代谢疾病的风险:一项为期三年的随访研究。
BMC Endocr Disord. 2021 Apr 28;21(1):85. doi: 10.1186/s12902-021-00754-1.
7
Comparison between metabolically healthy obesity and metabolically unhealthy obesity by different definitions among Mexican children.墨西哥儿童中不同定义下代谢健康型肥胖与代谢不健康型肥胖的比较
J Pediatr Endocrinol Metab. 2020 Feb 25;33(2):215-222. doi: 10.1515/jpem-2019-0077.
8
Long-Term Prognosis of Acute Myocardial Infarction Associated With Metabolic Health and Obesity Status.代谢健康与肥胖状况与急性心肌梗死的长期预后关系。
Endocr Pract. 2022 Aug;28(8):802-810. doi: 10.1016/j.eprac.2022.05.007. Epub 2022 May 30.
9
The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: A PRISMA-compliant article.代谢健康型肥胖的患病率、代谢风险及生活方式干预的效果:一项系统评价和荟萃分析:一篇遵循PRISMA规范的文章
Medicine (Baltimore). 2017 Nov;96(47):e8838. doi: 10.1097/MD.0000000000008838.
10
Life course factors associated with metabolically healthy obesity: a protocol for the systematic review of longitudinal studies.与代谢健康肥胖相关的生命历程因素:系统综述纵向研究的方案。
Syst Rev. 2018 Mar 27;7(1):50. doi: 10.1186/s13643-018-0713-x.

引用本文的文献

1
Metabolically Healthy Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Navigating the Controversies in Disease Development and Progression.代谢健康型肥胖与代谢功能障碍相关脂肪性肝病(MASLD):应对疾病发生发展中的争议
Curr Obes Rep. 2025 May 19;14(1):46. doi: 10.1007/s13679-025-00637-9.
2
IL-6 Affects Liver Metabolic Abnormalities Caused by Silicon Exposure by Regulating the PKC/YY1 Signaling Pathway.白细胞介素-6通过调节蛋白激酶C/阴阳1信号通路影响硅暴露引起的肝脏代谢异常。
Genes (Basel). 2025 Apr 16;16(4):456. doi: 10.3390/genes16040456.
3
Predictive modeling of lean body mass, appendicular lean mass, and appendicular skeletal muscle mass using machine learning techniques: A comprehensive analysis utilizing NHANES data and the Look AHEAD study.

本文引用的文献

1
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.AGA 临床实践指南:药物干预成人肥胖症。
Gastroenterology. 2022 Nov;163(5):1198-1225. doi: 10.1053/j.gastro.2022.08.045. Epub 2022 Oct 20.
2
Obesity Metabolic Phenotype, Changes in Time and Risk of Diabetes Mellitus in an Observational Prospective Study on General Population.在一项针对普通人群的观察性前瞻性研究中,肥胖代谢表型随时间的变化与糖尿病风险。
Int J Public Health. 2022 Sep 29;67:1604986. doi: 10.3389/ijph.2022.1604986. eCollection 2022.
3
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials.
利用机器学习技术对去脂体重、四肢瘦体重和四肢骨骼肌质量进行预测建模:利用 NHANES 数据和 LOOK AHEAD 研究进行的综合分析。
PLoS One. 2024 Sep 6;19(9):e0309830. doi: 10.1371/journal.pone.0309830. eCollection 2024.
4
Sedentary behavior, physical activity, sleep duration and obesity risk: Mendelian randomization study.静坐行为、身体活动、睡眠时间与肥胖风险:孟德尔随机化研究。
PLoS One. 2024 Mar 8;19(3):e0300074. doi: 10.1371/journal.pone.0300074. eCollection 2024.
司美格鲁肽对无糖尿病肥胖或超重患者体重减轻的疗效和安全性:一项随机对照试验的系统评价和荟萃分析
Front Pharmacol. 2022 Sep 14;13:935823. doi: 10.3389/fphar.2022.935823. eCollection 2022.
4
Factors of Obesity and Metabolically Healthy Obesity in Asia.亚洲肥胖症和代谢健康型肥胖的相关因素。
Medicina (Kaunas). 2022 Sep 13;58(9):1271. doi: 10.3390/medicina58091271.
5
The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy.纳曲酮-安非他酮疗法中早期体重减轻与体重维持之间的关系。
EClinicalMedicine. 2022 May 27;49:101436. doi: 10.1016/j.eclinm.2022.101436. eCollection 2022 Jul.
6
Fat Distribution Patterns and Future Type 2 Diabetes.脂肪分布模式与未来 2 型糖尿病。
Diabetes. 2022 Sep 1;71(9):1937-1945. doi: 10.2337/db22-0315.
7
Food as medicine? Exploring the impact of providing healthy foods on adherence and clinical and economic outcomes.食物即药物?探究提供健康食品对依从性以及临床和经济结果的影响。
Explor Res Clin Soc Pharm. 2022 Mar 18;5:100129. doi: 10.1016/j.rcsop.2022.100129. eCollection 2022 Mar.
8
Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.非酒精性脂肪性肝病(NAFLD):病理生理学、临床管理和减肥效果的综述。
BMC Endocr Disord. 2022 Mar 14;22(1):63. doi: 10.1186/s12902-022-00980-1.
9
Metabolome-Defined Obesity and the Risk of Future Type 2 Diabetes and Mortality.基于代谢组学定义的肥胖与未来 2 型糖尿病发病风险及死亡风险的相关性研究
Diabetes Care. 2022 May 1;45(5):1260-1267. doi: 10.2337/dc21-2402.
10
Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.司美格鲁肽,一种胰高血糖素样肽-1 受体激动剂,具有心血管获益,可用于 2 型糖尿病的治疗。
Rev Endocr Metab Disord. 2022 Jun;23(3):521-539. doi: 10.1007/s11154-021-09699-1. Epub 2022 Jan 7.